Biomerica Inc.

126 articles about Biomerica Inc.

• inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology

  5/18/2023

  Biomerica Inc., a global biomedical company leading the way in innovative gastroenterology solutions, announced a significant advance in the management of irritable bowel syndrome.

• Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).

  4/17/2023

  Biomerica, Inc. is pleased to announce that inFoods® IBS, a revolutionary new approach to alleviate Irritable Bowel Syndrome symptoms, is now available at the flagship office of Gastro Health in Miami, with plans expand into the other Gastro Health offices in the future.

• Biomerica Reports Q3 Fiscal 2023 Results

  4/14/2023

  Biomerica, Inc., a global provider of advanced medical diagnostic and therapeutic products, announced its fiscal third quarter and nine month results ended February 28, 2023.

• Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock

  3/7/2023

  Biomerica, Inc. announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock.

• Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock

  3/3/2023

  Biomerica, Inc. announced underwritten public offering. Biomerica is offering an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share.

• Biomerica Announces Proposed Underwritten Public Offering of Common Stock - March 02, 2023

  3/2/2023

  Biomerica, Inc., a global provider of advanced medical products, announced that it has commenced an underwritten public offering of its common stock.

• Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

  1/13/2023

  Biomerica, Inc., a global provider of advanced medical products, reported its second quarter fiscal 2023 financial results for the period ended November 30, 2022.

• Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

  1/10/2023

  Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board.

• Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAEExpands Commercialization Efforts in Areas with High Unmet Needs

  12/8/2022

  Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) for the EZ Detect™ Colon Disease test and the Aware® Breast Self Exam device.

• Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting

  11/2/2022

  Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) announced that data derived from a clinical study of InFoods® IBS was presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting.

• Walmart to Expand Sales of Biomerica’s Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores

  10/14/2022

  Biomerica, Inc. announced that under a General Merchandise Supplier Agreement with Walmart, the Company’s Aware® Breast Self Exam device will now be sold in over 2400 Walmart’s retail stores.

• Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022

  10/13/2022

  Biomerica, Inc., a global provider of advanced medical products, reported net sales for the three months ended August 31, 2022 of $1.67 million, versus net sales of $1.26 million for the same period in the previous year, a 30% increase.

• Biomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon

  9/29/2022

  Biomerica, Inc. announced that the Company’s Aware® Breast Self Exam device and EZ Detect Colon Disease test are now being sold on Amazon and fulfilled by Amazon.

• Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer

  8/30/2022

  Biomerica, Inc. announced plans to launch its InFoods® IBS test before calendar year end.

• Biomerica Reports Fiscal 2022 Year End Results

  8/29/2022

  Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2022 financial results.

• Biomerica to Participate at BTIG Biotech Conference

  6/23/2022

  Biomerica Inc. (NASDAQ: BMRA ) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person in New York City on Monday, August 8th and Tuesday August 9th , 2022.

• Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™

  5/12/2022

  Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products, announces CE Mark for its hp+detect™ diagnostic test that detects Helicobacter pylori (H. pylori) bacteria.

• Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population

  4/26/2022

  Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for hp+detect™, a new product that detects the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population.

• Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021

  4/14/2022

  Biomerica, Inc. today announced its fiscal third quarter and nine month results ended February 28, 2022.

• Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

  2/8/2022

  Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced positive topline results from the endpoint clinical trial of its InFoods® IBS diagnostic-guided therapy.